Skip to content

    Persistent Systems Q1 FY26 earnings call

    PERSISTENT
    Information Technology·23 Jul 2025
    Management Summary

    Persistent Systems delivered a healthy Q1 FY26, achieving 3.9% QoQ and 18.8% YoY revenue growth in USD, alongside robust EBIT margin expansion. The company secured strong TCV bookings of USD 520.8 million and saw significant client growth. Despite macroeconomic uncertainties, delayed ramp-ups, and a QoQ decline in the healthcare vertical, management expressed confidence in future growth, driven by AI-led strategies and a healthy pipeline, while maintaining a commitment to profitable growth and its FY27 $2 billion revenue target.

    Highlights

    8
    • Healthy revenue growth of 3.9% QoQ and 18.8% YoY in USD terms, marking 21st sequential quarter of growth.

    • EBIT margin at 15.5%, showing a 150 basis points improvement year-on-year despite unfavorable currency movement.

    • Profit after tax (PAT) grew 38.7% year-on-year to 4,249.4 million INR, with PAT margin at 12.7%.

    • Strong Total Contract Value (TCV) of USD 520.8 million, with new bookings TCV at USD 337.0 million.

    • Significant improvement in Return on Capital Employed (RoCE) by 510 basis points year-on-year to 43.8%.

    • Healthy year-on-year growth across various client buckets, with top 5 customers' revenue growing by 22.8% and top 100 by 22.4%.

    • BFSI vertical led growth at 30.7% year-on-year, followed by software high-tech (14.1%) and healthcare life sciences (12.4%).

    • North America grew by 17.4% and Europe by 37.5% year-on-year in USD terms.

    Concerns

    5
    • Healthcare life sciences vertical declined by 2.1% quarter-on-quarter due to planned transition of effort from on-site to offshore.

    • Unfavorable currency movements impacted EBIT margin by 40 basis points.

    • Higher amortization cost impacted EBIT margin by 40 basis points, which is expected to continue.

    • Delayed ramp-ups in some accounts and continued retention of on-site resources to de-risk projects impacted margins by 100 basis points.

    • Postponement of annual wage hike by a quarter due to uncertain business scenario.

    What Changed3

    vs Q2 FY26

    Guidance items5 → 4 (-1)Risks discussed3 → 6 (+3)Q&A highlights6 → 8 (+2)

    Key financials

    Single quarter

    08 metrics
    1. 01Revenue389.7 Mn+18.8%YoY
    2. 02Revenue33,335.9 Mn+21.8%YoY
    3. 03EBIT Margin15.5%
    4. 04EBIT5,178.1 Mn+34.8%YoY
    5. 05Profit After Tax4,249.4 Mn+38.7%YoY

    Segment breakdown

    BFSI
    30.7% Revenue Growth
    Software High-Tech and Emerging Industries
    14.1% Revenue Growth
    Healthcare Life Sciences
    12.4% Revenue Growth-2.1% Revenue Growth
    North America
    17.4% Revenue Growth
    Europe
    37.5% Revenue Growth
    India
    18.3% Revenue Growth
    Rest of the World
    -1.7% Revenue Growth
    List

    Order Book

    high confidence

    Total Value

    USD 520.8 million

    as of 2025-06-30

    quantified

    Inflow this qtr

    USD 337 million

    Execution

    our revenue conversion on a quarterly basis is a function of ACV bookings done in previous quarters, as well as the conversion from multi-year deals booked in previous years

    Pipeline

    deal pipeline tcv

    Pipeline is healthy, but not quantified.

    "The order book is healthy, and the company is reasonably confident of the growth journey, with larger deals in the pipeline."

    Source:
    Prepared remarks

    Capital allocation

    1
    medium confidence
    CategoryHeadline
    Liquidity

    Cash ₹307.8 million

    Total cash and investment saw an improvement this quarter and stood at Rs.307.8 million as on June 30, 2025.

    Guidance & targets

    4
    CategoryTargetPriority
    Revenue
    Revenue Goal
    2 billion dollars
    High
    Profitability
    EBIT Margin Improvement
    200-300 basis point
    High
    Tax
    Effective Tax Rate
    22.5% to 23.5%
    High
    Revenue Composition
    Europe Revenue Share
    15%
    Medium

    What to watch in Q2 FY26

    5

    Healthcare Vertical Growth Recovery

    next quarter
    CurrentDeclined 2.1% QoQ
    TargetReturn to growth

    Why it matters

    Healthcare is a key vertical, and its recovery from QoQ decline is important for overall growth trajectory.

    I don't think there will be further degrowth in the vertical. It will definitely be a growth vertical for us during the year.

    Risks & concerns

    6
    RiskSeverity

    Macroeconomic and geopolitical uncertainties

    Increased caution among customers due to macroeconomic and geopolitical uncertainties, leading to slower decision-making.Management acknowledged

    medium

    Delayed project ramp-ups and on-site resource retention

    Delayed ramp-ups in some accounts and retaining on-site resources to de-risk projects impacted margins by 100 basis points, particularly in healthcare life sciences.Management acknowledged

    medium

    Unfavorable currency movement

    Unfavorable currency movements impacted EBIT margin by 40 basis points.Management acknowledged

    low

    Higher amortization cost

    Higher amortization cost impacted margin by 40 basis points and is expected to continue without substantial increase.Management acknowledged

    low

    Postponement of annual wage hike

    Wage hike postponed by a quarter due to uncertain business scenario, with potential implications for attrition.Management acknowledged

    low

    Stress in Healthcare Life Sciences vertical

    Impact from tariffs (China supply chain) and federal/DOGE funding policies are causing stress, leading to cost control, vendor consolidation, and more offshoring.Management acknowledged

    medium

    Q&A highlights

    8

    “All I can say is, if you look at the overall growth, it was 3.9% in USD terms. The constant currency, the currency movements are not necessarily in our hands... If the environment becomes a little bit better and not just for us, for everyone, I think things will be easier.”

    Analyst questioned if 3.5-4% sequential growth is the new normal, and management acknowledged caution in the environment without giving specific forward-looking numbers.

    asked by Mehta Bhavik

    3 min read6 chapters

    Detailed Narrative

    01

    Q1 FY26 Financial Performance Overview

    Persistent Systems reported a robust Q1 FY26, with revenue reaching US $389.7 million, reflecting a healthy 3.9% quarter-on-quarter and 18.8% year-on-year growth. In constant currency terms, the growth was 3.3% QoQ, marking the 21st consecutive quarter of growth. The EBIT margin stood at 15.5%, improving by 150 basis points year-on-year, despite a 40 basis points impact from unfavorable currency movements and another 40 basis points from higher amortization costs. Profit after tax (PAT) grew 38.7% YoY to 4,249.4 million INR, translating to a PAT margin of 12.7%.

    02

    Order Book and Client Movement

    The company secured a Total Contract Value (TCV) of USD 520.8 million for the quarter, with new bookings contributing USD 337.0 million. The Annual Contract Value (ACV) from this TCV was USD 385.3 million, including USD 211.8 million from new bookings. Client growth was healthy across categories, with top 5 customers' revenue increasing by 22.8% YoY and top 100 accounts growing by 22.4% YoY. The number of customers with greater than $5 million revenue significantly increased from 41 to 56 over the last year.

    03

    Geographic and Vertical Performance

    Geographically, North America grew by 17.4% YoY, Europe by 37.5% YoY, and India by 18.3% YoY in USD terms. From an industry segment perspective, BFSI led the growth with a 30.7% YoY increase, followed by software high-tech and emerging industries at 14.1% YoY, and healthcare life sciences at 12.4% YoY. However, the healthcare life sciences vertical experienced a 2.1% QoQ decline, primarily due to a planned transition of efforts from on-site to offshore in larger customer accounts.

    04

    Margin Walkthrough and Operational Metrics

    A quarter-on-quarter EBIT margin walkthrough revealed a net decrease of 10 basis points. Tailwinds included a lower ESOP cost, which helped by 230 basis points. Headwinds included the absence of earn-out reversal (60 bps impact), delayed ramp-ups and on-site resource retention (100 bps impact), higher amortization (40 bps impact), and unfavorable currency movements (40 bps impact). The company postponed its annual wage hike by a quarter due to the uncertain business scenario. Billed DSO improved by 2 days to 56 days, and unbilled DSO improved by 3 days to 20 days. Total headcount reached 25,314, an increase of 746 QoQ, while trailing 12-month attrition stood at 13.9%.

    05

    AI Progress and Strategic Focus

    Persistent is pivoting to an AI-led platform-driven strategy, focusing on 'AI for Technology' and 'AI for Business'. The company launched SAVA 3.0, an AI-powered digital engineering platform, which was built leveraging SASVA itself, demonstrating its productivity promise. SASVA is backed by over 55 patents and is seeing good traction in enhancing engineering productivity and tech debt remediation. For 'AI for Business', Persistent is helping enterprises modernize data architecture and build custom platforms, leveraging hyperscaler partners. The company also highlighted its investments in a Digital Trust Layer for Responsible AI, security, and governance, strengthened by the Arrka acquisition.

    06

    Strategic Outlook and Growth Aspirations

    Management reiterated its commitment to achieving a revenue goal of $2 billion by the end of FY27, aiming for a compounded annual growth rate of 19%-20%. This growth is expected to be a combination of organic expansion and tuck-in acquisitions, with a focus on capability-led smaller deals. The company also aims for Europe to contribute 15% of its revenue in the next 2-3 years. Despite increased caution among customers and a longer decision-making cycle, Persistent expressed confidence in its growth journey, emphasizing profitable growth over growth at any cost.

    This is an AI-generated summary of a publicly available earnings call transcript.